Two patterns of alanine aminotransferase increase to predict long-term viral response in chronic hepatitis B patients: Virus- or host-induced?

Antiviral Therapy

Volumn 16, Issue 3, 2011, Pages 299-307

  You, Hong ^a,b   Wu, Xiaoning ^a,b   Ou, Xiaojuan ^a,b   Ma, Hong ^a,b   Wang, Qianyi ^a,b   Liu, Tianhui ^a,b   Cong, Min ^a,b   Wang, Ping ^a,b   Wang, Baoen ^a,b   Jia, Jidong ^a,b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ENTECAVIR; GAMMA INTERFERON; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; TELBIVUDINE; VIRUS DNA;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HELPER CELL; HEPATITIS B; HEPATITIS B VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEROCONVERSION; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS CELL INTERACTION;

ADENINE; ADULT; AGED; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DNA, VIRAL; FEMALE; GUANINE; HEPACIVIRUS; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-GAMMA; LAMIVUDINE; MALE; MIDDLE AGED; NUCLEOSIDES; PHOSPHONIC ACIDS; PREDICTIVE VALUE OF TESTS; PYRIMIDINONES; T-LYMPHOCYTES; TREATMENT OUTCOME; UP-REGULATION; YOUNG ADULT;

EID: 79959393817     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1758     Document Type: Article

References (19)

1. Perrillo RP. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 2001; 120:1009-1022. (Pubitemid 32193199)
2. Yuen MF, Yuan HJ, Hui CK, et al. A large population study of spontaneous HBeAg seroconversion and acute exacerbation of chronic hepatitis B infection: implications for antiviral therapy. Gut 2003; 52:416-419.
3. Tsai SL, Chen PJ, Lai MY, et al. Acute exacerbations of chronic type B hepatitis are accompanied by increased T cell responses to hepatitis B core and e antigens. Implications for hepatitis B e antigen seroconversion. J Clin Invest 1992; 89:87-96.
4. Nair S, Perrillo RP. Serum alanine aminotransferase flares during interferon treatment of chronic hepatitis B: is sustained clearance of HBV DNA dependent on levels of pretreatment viremia? Hepatology 2001; 34:1021-1026.
5. Flink HJ, Sprengers D, Hansen BE, et al. Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during peg-interferon alpha-2b therapy. Gut 2005; 54:1604-1609. (Pubitemid 41531780)
6. Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005; 365:123-129. (Pubitemid 40091801)
7. Tang TJ, Kwekkeboom J, Laman JD, et al. The role of intrahepatic immune effector cells in inflammatory liver injury and viral control during chronic hepatitis B infection. J Viral Hepat 2003; 10:159-167. (Pubitemid 36629663)
8. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352:2682-2695. (Pubitemid 41007823)
9. You H, Ma H, Liu T, et al. Different models of HBeAg seroconversion predicated by on-treatment ALT and HBV DNA profiles. J Viral Hepat 2009; 16:876-882.
10. Chinese Society of Hepatology, Chinese Medical Association, Chinese Society of Infectious Diseases, Chinese Medical Association. [The guidelines of prevention and treatment for chronic hepatitis B.] Zhonghua Gan Zang Bing Za Zhi. 2005; 13:881-891. Chinese.
11. Lok AS, McMahon BJ, Practice Guidelines Committee, American Association for the Study of Liver Diseases (AASLD). Chronic hepatitis B: update of recommendations. Hepatology 2004; 39:857-861.
12. Kumar M, Chauhan R, Gupta N, et al. Spontaneous increases in alanine aminotransferase levels in asymptomatic chronic hepatitis B virus-infected patients. Gastroenterology 2009; 136:1272-1280.
13. You H, Liu Y, Cong M, et al. HBV genes induce cytotoxic T-lymphocyte response upon adeno-associated virus (AAV) vector delivery into dendritic cells. J Viral Hepat 2006; 13:605-612. (Pubitemid 44232544)
14. Massetto B, Menzaghi B, Giambelli C, et al. The good and evil of flare: flares in hepatitis B virus chronic hepatitis. Eur J Gastroenterol Hepatol 2007; 19:821-823. (Pubitemid 47266715)
15. ter Borg MJ, Hansen BE, Bigot G, et al. ALT and viral load decline during PEG-IFN alpha-2b treatment for HBeAg-positive chronic hepatitis B. J Clin Virol 2008; 42:160-164.
16. ter Borg MJ, van Zonneveld M, Zeuzem S, et al. Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: relation to treatment response. Hepatology 2006; 44:721-727.
17. Kondo Y, Asabe S, Kobayashi K, et al. Recovery of functional cytotoxic T lymphocytes during lamivudine therapy by acquiring multi-specificity. J Med Virol 2004; 74:425-433. (Pubitemid 39281641)
18. Sarin SK, Sandhu BS, Sharma BC, et al. Beneficial effects of 'lamivudine pulse' therapy in HBeAg-positive patients with normal ALT. J Viral Hepat 2004; 11:552-558.
19. Evans A, Riva A, Cooksley H, et al. Programmed death 1 expression during antiviral treatment of chronic hepatitis B: impact of hepatitis B e-antigen seroconversion. Hepatology 2008; 48:759-769.